Real‐world use of second‐generation integrase strand transfer inhibitors ( <scp>INSTI</scp> ) as switch therapy in the prospective <scp>ANRS</scp> ‐ <scp>CO3</scp> ‐ <scp>AquiVIH</scp> ‐ <scp>NA</scp> cohort
In this real-world cohort, treatment persistence 18 months after therapy switch was similar for B/F/TAF, DTG/RPV and DTG/3TC, but significantly lower for DTG/3TC/ABC. All regimens maintained high levels of viral suppression. Furthermore, the cohort illustrates the disease burden experienced by middle-aged and elderly people living with HIV and highlights the importance of adapting ART to the specific needs of this population.
Authors
- L. Alleman (ORCID: https://orcid.org/0000-0002-8568-6982)
- Sandrine Reigadas
- Y Gérard
- Gwenae Le Moal
- A. Riché (ORCID: https://orcid.org/0000-0002-2592-3827)
- D. Neau
- A. Perrier
- E. Lazaro
- F. Bonnet
- O. Leleux
- G. Barrière
- P. Duffau
- C. Cazanave
- M.‐A. Vandenhende
- M. Hessamfar
- A. Peyrouny‐Mazeau
Institutions
- Université de Bordeaux (FR)
- Inserm (FR)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Bordeaux Population Health (FR)
- Hôpital Saint-André (FR)
- Centre Hospitalier Universitaire de Poitiers (FR)
- Hôpital Pellegrin (FR)
- Hôpital Cardiologique du Haut-Lévêque (FR)
- Centre Hospitalier d'Angoulême (FR)
- Centre Hospitalier de la Côte Basque (FR)
- Centre Hospitalier de Dax –Côte d’Argent (FR)
- Gilead Sciences (France) (FR)
Publication Details
- Journal
- HIV Medicine
- Published
- 2026-03-07
- DOI
- https://doi.org/10.1111/hiv.70220
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00